Movement Alert|TG Therapeutics Rises 6.88% in Regular Trading, Trading at $56.5

Market Focus
06/22

On June 22, TG Therapeutics rose 6.88% in regular trading, trading at $56.5 USD/share, with Turnover of $17.88 million.

Within the Biotechnology sector where TG Therapeutics belongs, among individual stocks, Apogee Therapeutics up 46.82%, AbbVie up 4.45%, Gilead Sciences up 0.05%, Regeneron Pharmaceuticals down 0.74%, Moderna down 2.76%.

TG Therapeutics is a commercial stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its product BRIUMVI, an anti-CD20 monoclonal antibody, has been approved in the US, EU, and UK for the treatment of adult patients with relapsing forms of multiple sclerosis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10